 |
||
 |
|
|
CURRICULUM VITAE
Charles P. Andrews, MD, CPI
Diagnostics Research Group
Director of Clinical Research
4410 Medical Drive, Suite 360 and 320
San Antonio, Texas 78229
Phone (210) 692-7157
Fax (210) 692-1999
[Return to Experience & Capabilities Page]
Education & Training:
1971: The University of Texas at Austin; B.A., (Undergraduate)
1975: The University of Texas Southwestern Medical School, Dallas; M.D. (Medical School)
1975-1976: Bexar County Hospital and Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas (Straight Medicine Internship)
1976-1978: Bexar County Hospital and Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas (Medicine Residency)
1978-1980: The University of Texas Health Science Center, San Antonio (Pulmonary Disease)
Current Positions:
1982-Present: Pulmonary Physician in private practice, San Antonio, Texas
2000-Present: Director of Clinical Research-Diagnostics Research Group, San Antonio, Texas
2007-Present: Managing Partner – Pulmonary Physicians
Certification & Licensure:
Licensure:
1975: MD-Texas
Certification:
1978: American Board of Internal Medicine
1980: Subspecialty Board of Pulmonary Disease
2002: Clinical Investigator Certification, Association of Clinical Research Professionals
Professional Appointments:
1981-1982: Assistant Professor of Medicine, The University of Texas Health Science Center at San Antonio, Texas
1980-1981: Medical Director, Medical Intensive Care Unit, Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas
1982-Present: Clinical Associate Professor of Medicine, University of Texas Health Science Center, San Antonio, Texas
1982-Present: Staff Physician, Southwest Texas Methodist Hospital, San Antonio, Texas
1982-Present: Staff Physician, St. Luke’s Lutheran Hospital, San Antonio, Texas
1982-Present: Staff Physician, Methodist Specialty and Transplant Hospital, San Antonio, Texas
1985-1998: Staff Physician, Humana Women’s Hospital, San Antonio, Texas
1986-2002: Staff Physician, St. Rose Hospital, San Antonio, Texas
1999-Present: Staff Physician, Memorial Hospital, Gonzales, Texas
2000-Present: Staff Physician, Uvalde Memorial Hospital, San Antonio, Texas
2000-Present: Staff Physician, Life Care Hospital, San Antonio, Texas
2000-Present: Staff Physician, Texan Hospital, San Antonio, Texas
Honors:
1970: Phi Beta Kappa (Undergraduate)
1971: Aesculapius Award for Highest Grade Point Average of a pre-medical student at The University of Texas, Austin
1999: Listed in Who’s Who
2001: Texas Organ Sharing Alliance Award for Healthcare Professionals
2003: Private Practice Leadership Development, American College of Chest Physicians
2005: Listed in Consumer’s Guide to Top Doctors
Finalist Cecile Lehman Mayor Research Forum, American College of Chest Physicians
Fellow American College of Chest Physicians
Fellow American College of Physicians
Professional Organizations:
• American Academy of Allergy, Asthma and Immunology
• American College of Allergy, Asthma and Immunology
• Fellow, American College of Physicians
• American Thoracic Society
• Association of Clinical Research Professionals
• Bexar County Medical Society
• Drug Information Association
• Fellow, American College of Chest Physicians
• Society of Critical Care Medicine
• Texas Medical Association
• Chairman, Section on Disease of the Chest 1985-1986
• Texas Society for Respiratory Care
• American Academy of Pharmaceutical Physicians
• Medical Group Management Association
Community Service:
• President, South Texas Organ Bank 1993-1998; Currently Board Member and member of the Executive Committee
• Co-chair for Fund Raising for Nurses’ House for Habitat for Humanity 1994
• Board Member, Alumni Association, University of Texas Southwestern Medical School, Dallas, Texas 2004-2006
• Judge for Health Sciences, San Antonio Regional Science Fair 2005
• Board of Trustees, Keystone School, San Antonio, Texas 2009
Previous Positions & Committee Memberships:
• Medical Director Intensive Care Unit, Southwest Texas Methodist Hospital
• Chairman Section of Diseases of the Chest, Texas Medical Association
• Chairman of Pulmonary Department, Methodist Specialty and Transplant Hospital
• Member of the Executive Committee, Southwest Texas Methodist Hospital
• Member of the Search Committee for Medicine Department Chairman, University of Texas Health Science Center, San Antonio, Texas 1978
• Medical Director, Intensive Care Unit, Rehabilitation Institute of San Antonio, Texas 1988-2000
• Medical Director, Pulmonary Care, Rehabilitation Institute of San Antonio, Texas 1988-2000
• President of Medical Staff, Rehabilitation Institute of San Antonio, Texas 2000
CLINICAL RESEARCH:
• Comparative Antibiotic Study in the Treatment of Acute Exacerbation of Chronic Bronchitis. Phase III. 1999-2000. Principal Investigator
• Inpatient Antibiotic Study of the Treatment of Hospital Acquired Pneumonia. Phase III. 1999. Principal Investigator
• Asthma Study. Phase II. 2000-2001. Principal Investigator
• Asthma/COPD: A Non-Comparative Study to Assess XXXX in Patients with Bronchospasm. Phase IV. 2000. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2000-2001. Principal Investigator
• Chronic Obstructive Pulmonary Disease Study- Anti-inflammatory. Phase III. 2001. Principal Investigator
• Asthma. Bronchodilator. Phase IV. 2000-2001. Principal Investigator
• Inpatient Antibiotic Study of the Treatment of Community- Acquired Pneumonia. Phase IV. 2000-2001. Principal Investigator
• Acute Exacerbation of Chronic Bronchitis. Phase III. 2001.Principal Investigator
• Inpatient Antibiotic Study of the Treatment of Community-Acquired Pneumonia. Phase III. 2001. Principal Investigator
• Acute Bacterial Exacerbation of Chronic Bronchitis Phase III. 2002. Sub-Investigator
• Chronic Obstructive Pulmonary Disease Study. Phase V. 2002. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2001-2002. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2001-2002. Principal Investigator
• Asthma. Phase III. 2002. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIIb. 2001-2002. Principal Investigator
• Seasonal Allergic Rhinitis and Concomitant Asthma. Phase III. 2001-2002. Principal Investigator
• Diagnosis of Lung Cancer by Sputum Cytology. Phase II. 2002. Principal Investigator
• Severe Sepsis Study. Inpatient. Phase II. 2002. Sub-Investigator
• Asthma. Phase II. 2002. Principal Investigator
• Chronic Obstructive Pulmonary Disease Study. Phase IV. 2002. Principal Investigator
• Chronic Obstructive Pulmonary Disease Study. Phase II. 2003 Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2003. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2002. Principal Investigator
• Asthma Phase III. 2002–2003. Principal Investigator
• Acute Exacerbation of Chronic Bronchitis Phase III. 2002. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III.2002. Principal Investigator
• Asthma. Phase III. 2002–2003. Principal Investigator
• Perennial Allergic Rhinitis. Phase IIIa. 2002–2003. Principal Investigator
• Asthma. Phase III. 2003. Sub-Investigator
• Seasonal Allergic Rhinitis and Concomitant Asthma. Phase IV. 2002 – 2003. Principal Investigator
• Asthma. Phase III. 2003. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2003. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IV. 2003. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IV. 2003. Principal Investigator
• Seasonal Allergic Rhinitis. Phase II. 2003-2004. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2003-2004. Principal Investigator
• Inpatient Antibiotic Study of the Treatment of Community- Acquired Pneumonia. Phase IIV. 2003-2004. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase II. 2003. Principal Investigator
• Perennial Allergic Rhinitis. Phase III. 2003. Principal Investigator.
• Seasonal Allergic Rhinitis and Concomitant Asthma. Phase IV. 2004. Principal Investigator
• Perennial Allergic Rhinitis. Phase III. 2003-2004. Principal Investigator
• Vulvovaginal Candidiasis. Phase IV. 2003. Sub-Investigator
• Hypertension.Phase III. 2003-2004. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IV. 2004. Principal Investigator.
• Asthma Study. Phase III. 2003-2004. Principal Investigator
• Asthma Study. Phase III. 2003-2004. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase II. 2003-2004. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2004. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2003-2004. Sub-Investigator
• Chronic Obstructive Pulmonary Disease/Asthma Inpatient Study. Phase IV. 2003. Principal Investigator
• Inpatient Antibiotic Study of the Treatment of Community Acquired Pneumonia. Phase III. 2003-2004. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2004. Principal Investigator
• Inpatient Bronchoscopy Sedation Study. Phase III. 2004-2005.
• Asthma. Phase III. 2005. Principal Investigator
• Asthma Phase IIa. 2004-2005. Principal Investigator
• Asthma. Phase IV. 2003. Principal Investigator
• Pulmonary Arterial Hypertension. Phase III. 2004. Sub-Investigator
• Asthma. Phase III. 2004. Principal Investigator
• Seasonal Allergic Rhinitis. Phase II. 2005. Principal Investigator
• Asthma. Phase II. 2005. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2005. Principal Investigator
• Stress Urinary Incontinence. Phase IV. 2004-2005. Principal Investigator
• Osteoporosis. Phase IIIB. 2004-2005. Principal Investigator
• Parkinson’s Disease. Phase IIIb. 2004-2005. Sub-Investigator.
• Uncomplicated Hypertension. Phase III. 2004-2005. Principal Investigator
• Inpatient Complicated Urinary Tract Infection. Phase IIb. 2004-2005. Principal Investigator
• Pulmonary Arterial Hypertension. Phase III. 2004-2005. Sub-Investigator
• Female Dyspepsia. Phase III. 2004-2006. Principal Investigator
• Pulmonary Arterial Hypertension. Phase III. 2004-2007. Sub-Investigator
• Seasonal Allergic Rhinitis. Phase III. 2005. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IV. 2005. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2004-2005. Principal Investigator
• Asthma/Allergy. Phase IV. 2005. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator
• Chronic Obstructive Pulmonary Disease/Asthma. Phase IIIb. 2005. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III Bioequivalence. 2006. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2005. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIb. 2006. Principal-Investigator
• Osteoporosis. Phase IIIb. 2005. Principal Investigator
• Diabetes. Phase II. 2005. Principal Investigator
• Cardiovascular Event Prevention. Phase III. 2005. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IV. 2006. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Observational. 2006. Principal Investigator
• Acute Exacerbation Chronic Obstructive Pulmonary Disease. Phase IV. 2006. Principal Investigator
• Acute Exacerbation of Chronic Bronchitis/Chronic Obstructive Pulmonary Disease. Phase II. 2006. Principal Investigator
• Seasonal Allergic Rhinitis. Bioequivalence. 2006. Principal-Investigator
• Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator
• Seasonal Allergic Rhinitis. Questionnaire. 2006. Principal Investigator
• Pulmonary Arterial Hypertension / Chronic Obstructive Pulmonary Disease. Phase IIa. 2006. Sub-Investigator
• Diabetes. Phase III. 2006-2007. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IV. 2007. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2006. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2006-2007. Principal Investigator
• Seasonal Allergic Rhinitis. Bioequivalence. 2006-2007. Principal-Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2006. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2005-2007. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2006-2007. Principal Investigator
• Dyspepsia. Phase II. 2006. Principal Investigator
• Dyslipidemia. Phase III. 2006. Principal Investigator
• Dyslipidemia. Phase III. 2006. Principal Investigator
• Abdominal Pain. Phase II. 2006. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase II. 2006-2007. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2007. Principal Investigator
• Asthma. Phase IIb. 2007. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2007. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIIb. 2007. Principal Investigator
• Pulmonary Arterial Hypertension. Phase III. 2006-2007. Sub-Investigator
• Diabetes. Phase III. 2006-2007. Principal-Investigator
• Dyslipidemia. Phase III. 2006-2007. Principal Investigator
• Pulmonary Arterial Hypertension. Phase IV. 2006-2008. Sub-Investigator
• Hyperlipidemia. Phase III. 2006-2008. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIIb. 2003-2007. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIb. 2007. Principal Investigator
• Asthma. Phase III. 2007. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IV. 2007. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2007. Principal Investigator
• Perennial Allergic Rhinitis. Phase III. 2006-2007. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IV. 2007-2008. Principal Investigator
• Seasonal Allergic Rhinitis. Phase II. 2007-2008. Principal Investigator
• Osteoarthritis of the Knee. Phase II. 2007. Principal Investigator
• Irritable Bowel Syndrome. Phase III. 2007. Principal Investigator
• Irritable Bowel Syndrome. Phase III. 2007. Principal Investigator
• Hypertension. Phase III. 2007. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2007-2008. Principal Investigator
• Seasonal Allergic Rhinitis. Phase IIb. 2007-2008. Principal Investigator
• Seasonal Allergic Rhinitis. Phase II. 2008. Principal Investigator
• Seasonal Allergic Rhinitis. Questionnaire. 2008. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2008. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase II/III. 2007-2008. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2008. Principal investigator
• Osteoarthritis. Phase III. 2007-2008. Principal Investigator
• Herpes Zoster Vaccine. Phase IV. 2007-2008. Principal Investigator
• Idiopathic Pulmonary Fibrosis. Phase III. 2007. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2006-2008. Principal Investigator
• Asthma. Phase IV. 2007-2008. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase II. 2008. Principal Investigator
• Pulmonary Arterial Hypertension. Device. 2008. Sub-Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIb. 2007-2008. Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2008-2009. Principal Investigator
• Osteoarthritis. Phase III. 2007-2008. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III Extension. 2008-2009. Principal Investigator
• Asthma. Phase IV. 2008. Principal Investigator
• Osteoarthritis of the Knee. Phase II. 2008. Principal Investigator
• Osteoarthritis of the Knee. Phase II. 2008. Principal Investigator
• Pneumonia Vaccine. Phase III. 2008. Principal Investigator
• Pneumonia Vaccine, Phase III. 2008. Principal Investigator
• Hypercholesterolemia. Phase III. 2008-2009. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIb. 2008-2009
Principal Investigator
• Seasonal Allergic Rhinitis. Phase III. 2009. Principal Investigator
• Asthma. Phase II. 2008 – 2009. Principal Investigator.
• Osteoarthritis of the Knee. Phase II. 2008. Principal Investigator
• Hypercholesterolemia. Phase III. 2009. Principal Investigator
• Chronic Constipation. Phase III. 2008-2009. Principal Investigator
• Asthma. Phase II. 2008. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2009. Sub-Investigator
• Abdominal Pain. Phase II. 2009. Principal Investigator
• Chronic Constipation/Irritable Bowel Syndrome Safety. Phase III. 2008. Principal Investigator
• Hypertension. Phase IV. 2008. Principal Investigator
• Chronic Constipation/Irritable Bowel Syndrome. Phase III. 2009. Sub-Investigator
• Hypertension/Diabetes. Phase IV. 2008. Principal Investigator
• Pulmonary Arterial Hypertension. Phase III. 2008. Sub-Investigator
• Pulmonary Arterial Hypertension. Phase III. 2008. Sub-Investigator
• Pulmonary Arterial Hypertension. Phase III. 2009. Sub-Investigator
• Osteoarthritis of the Knee. Phase III. 2008-2009. Principal Investigator
• Osteoarthritis of the Hip. Phase III. 2008-2009. Principal Investigator
• Osteoarthritis of the Knee. Phase III. 2008. Principal Investigator
• Osteoarthritis of the Knee/Hip. Phase III. Extension Study. Principal Investigator
• Hypertension. Phase III. 2009. Sub-Investigator
• Perennial Allergic Rhinitis. Phase IV. 2008-2009. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIa. 2009. Sub-Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. 2009. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase III. Extension Study. Principal Investigator
• Idiopathic Pulmonary Fibrosis. Phase IIIb. Extension study 2008. Principal Investigator
• Asthma. Phase II. 2009. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase II. 2009. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIIb. 2009. Principal Investigator
• Chronic Obstructive Pulmonary Disease. Phase IIa. 2009. Sub-Investigator
• Seasonal Allergic Rhinitis. Phase II/III. 2009. Principal Investigator
• Pulmonary Arterial Hypertension. Phase III. 2009. Principal Investigator
• Rota Virus Vaccine. Phase I. 2009. Principal Investigator
• Flu Vaccine. Phase IV. 2009. Principal Investigator
Investigator Training:
• “Manage Your Investigative Site To Be A Winning Operation”
Drug Information Association
February 5, 2001, Chicago. IL
• “Protecting Study Volunteers in Research”
Study Program of the University of Rochester school of Medicine
May 2001.
• “Implementation of Good Clinical Practices and Quality Assurance Auditing”
Bruce M. Wagman, MBA and Michael R. Hamrell, Ph.D.
Drug Information Association Tutorial
July 8, 2001, Denver. CO
• “Investigator Training: Responsible Conduct of Clinical Research - Ethics and Standards”
Lewis Smith, M.D.
Drug Information Association Tutorial
July 8, 2001, Denver. CO
• “Conflicts of Interest and Recruitment of Subjects for Clinical Research: Legal, Regulatory and Ethical Concerns”
David Foster, JD, MA
Drug Information Association
July 9, 2001, Denver. CO
• “Developing Investigator and Sponsor Relationships:Incorporating and Enhancing Clinical Research in a Physician Group Practice”
David B. Millard
Drug Information Association
July 9, 2001, Denver.CO
• “Electronic Data Capture- What’s Next?”
Paul A. Bleicher, M.D., Ph.D.
Drug Information Association
July 10, 2001, Denver. CO
• “Clinical Investigator Certification Examination”
Association of Clinical Research Professionals
November 9, 2002, Dallas, Texas
• American College of Allergy, Asthma & Immunology Annual Meeting
November 15 – 20, 2002
• Focus: Achieving Your Highest Priorities
Franklin Covey
March 3, 2003, San Antonio, Texas
• “How to Manage Clinical Trial finances”
Clinical Research Site Training
April 14-15, 2003, Dallas, Texas
• Association of Clinical Research Professionals
National Meeting
June 2004, San Diego, California
• “The 4 Disciplines of Execution”
Franklin Covey
July 27, 2004, San Antonio, Texas
• “Tearing Down Walls: Enhancing Sponsor-Investigator Communication”
American Academy of Pharmaceutical Physicians
11th Annual Meeting
November 4-6, 2004, Atlanta, Georgia
• “Investigator Practical Issues”
American Academy of Pharmaceutical Physicians
11th Annual Meeting
November 4-6, 2004, Atlanta, Georgia
• “Preserving Trust, Promoting Clinical Research”
American Academy of Pharmaceutical Physicians
11th Annual Meeting
November 4-6, 2004, Atlanta, Georgia
• “How Do We Improve Regulatory Compliance” American Academy of Pharmaceutical Physicians
11th Annual Meeting
November 4-6, 2004, Atlanta, Georgia
• “Relationships Between the CRO, Sponsor and the Investigator”
American Academy of Pharmaceutical Physicians
11th Annual Meeting
November 4-6, 2004, Atlanta, Georgia
• “Integrated Approach To Fast Tracking Clinical Trial Recruitment”
American Academy of Pharmaceutical Physicians
11th Annual Meeting
November 4-6, 2004, Atlanta, Georgia
• Successful Post-Marketing Studies: The Sponsor’s Point of View
American Academy of Pharmaceutical Physicians
11th Annual Meeting
• Disease Management: Standardization and Reporting of Outcomes”
November 4-6, 2004, Atlanta, Georgia
• “Issues in Site Indemnification”
American Academy of Pharmaceutical Physicians
11th Annual Meeting
November 4-6, 2004, Atlanta, Georgia
• How to Market your Clinical Research Services to Sponsor Companies and CRO’s”
Mary E. Briggs-Focus Incorporated
February 3, 2005, San Antonio, Texas
• “FDA Inspections of Clinical Sites-FDA Expectations, and How to Prepare for an FDA Inspection”
Association of Clinical Research Professionals
Presented by Patricia Holobaugh
September 27, 2005, San Antonio, Texas
• “American College of Chest Physicians”
Annual Meeting
October 23-25, 2006, Salt Lake City, Utah
• “American College of Allergy, Asthma and Immunology”
Annual Meeting
November9-13, 2007, Dallas, Texas
• “American Academy of Allergy Asthma and Immunology”
Annual Meeting
March 14-18, 2008, Philadelphia, PA
• “Understanding FDA’s New Draft Guidance Regarding Supervisory Responsibilities of Investigators Requiring Detailed Planning”
Presented by Barnett Educational Services
June 11, 2008, San Antonio, Texas
• American Thoracic Society
Annual Meeting
May 16 – 19, 2009, San Diego, California
• Physician’s Viewpoint Network
23rd Annual Meeting
November 6, 2009, San Antonio, Texas
• American College of Allergy, Asthma and Immunology
Annual Meeting
November 6 – 10, 2009, Miami, Florida
Bibliography:
• Andrews, C.P., Coalson, J.J., Smith, J.D., and Johanson, W.G., Jr.: Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury (ARDS). Chest 1981; 80:254-258.
• Andrews, C.P., and Weiner, M.H.: Immunodiagnosis of invasive pulmonary aspergillosis: Fungal antigen detected by radioimmunoassay in bronchoalveolar lavage fluid. Am. Rev. Resp. Dis; 1981. 124:60-64.
• Andrews, C.P., and Weiner, M.H.: Aspergillus antigen detection from patients with invasive aspergillosis and aspergillomas. Am. J. Med; 1982. 73:372-80.
• Bell, R., Andrews, C.P.: Pleural effusions: Meeting the diagnostic challenge. Geriatrics 1985. 40, 4:101.
• acobs, R.L., Andrews, C.P., and Jacobs, F.O.: Hypersensitivity pneumonitis treated with an electrostatic dust filter. Ann. Int. Med; 1989. 110:115-118.
• Peters, J.I., Bell, R.C., Prihoda, T.J., Harris, G., Andrews, C., and Johanson, W.G.: Clinical determinants of abnormalities in pulmonary functions in survivors of the adult respiratory distress syndrome. Am. Rev. Respir. Dis; 1989. 139:1163-1168.
• Andrews, C.P., Smith, J.D., and Johanson, W.G., Jr.: Pulmonary effects of methylmethacrylate vapor exposure in dental students. Clin. Res; 1979(Abstract) 27:759A.
• Andrews, C.P., and Shaw, J.O.: In vitro functional capacity of bronchoalveolar neutrophils. Am. Rev. Respir. Dis; 1980. 121:54.
• Andrews, C.P., Coalson, J.J., Smith, J.D., and Johanson, W.G., Jr.: Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury (ARDS). Chest; 1980 (Abstr.).78:507.
• Andrews, C.P., and Weiner, M.H.: Diagnosis of invasive pulmonary aspergillosis: Fungal antigen detected by radioimmunoassay in bronchoalveolar lavage fluid. Chest; 1980(Abstr.) 78:507. Presented at the Cecile Lehman Mayer Research Forum of the 46th Annual Scientific Assembly of the American College of Chest Physicians, October 29, 1980.
• Shaw, J.O., Kolb, W.P., Andrews, C.P., Fine, R., and Johanson, W.G., Jr.: C5-derived chemotactic peptides and neutrophils in the alveolus as potential pathogenic factors in interstitial fibrosis. Presented at the International Colloquium on Pulmonary Fibrosis, London, England, February, 1980.
• Shaw, J.O., Wetsel, R.A., Andrews, C.P., and Kolb, W.P.: C5 cleaving enzyme(s) in the airspaces of patients with acute respiratory distress syndrome. Clin. Res. 28:842A, 1980 (Abstr.).
• Andrews, C.P., Coalson, J.J., Smith, J.D., and Johanson, W.G., Jr.: Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury (ARDS). Presented to Third World Congress on Intensive and Critical Care Medicine, May, 1981. Crit. Care Med; 1981 (Abstr.) 9:197.
• Shaw, J.O., Ferrigni, K.S., Wetsel, R.A., Andrews, C.P., and Kolb, W.P.: C5 cleaving enzyme(s) in the airspaces of patients with acute respiratory distress syndrome. Am. Rev. Respir. Dis; 1981 (Abstr.) 123:51.
• Andrews, C.P., and Weiner, M.H.: Effects of bronchoalveolar lavage fluid concentration on radioimmunoassay detection of Aspergillus antigen in experimental and human infection. Am. Rev. Respir. Dis; 1981(Abstr.). 123:260.
• Andrews, C.P., Aufdemorte, T., and Johanson, W.G., Jr.: Systemic candidiasis associated with progressive pulmonary cavitations. Submitted.
• Andrews, C.P. and Weiner, M.H.: Radioimmunoassay detection of aspergillus carbohydrate in sequential bronchoalveolar lavages during pulmonary aspergillosis. Chest ; 1981(Abstr.). 80:341-2.
• Andrews, C.P., Drutz, D.J., Coalson, J.J., and Johanson, W.G., Jr.: Acute cardiorespiratory toxicity of miconazole in dogs. Abstracts of the 21st ICAAC.Presented at the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November 6, 1981.
• Andrews, C.P., and Weiner, M.H.: Improved diagnosis of invasive aspergillosis by detection of fungal antigen in bronchoalveolar cell pellets and serum. Clin. Res; 1981(Abstr.). 29:844A.
• Andrews, C.P., Smith, J.D., and Johanson, W.G., Jr.: Clinical determinants of persistent abnormalities of diffusing capacity in survivors of adult respiratory distress syndrome. Chest 82:214 (Abstr.).
• Campbell, G.D., Andrews, C.P., Smith, J.D., and Johanson, W.G., Jr.: The adult respiratory distress syndrome due to non-pulmonary sepsis: Determinants of survival. Crit. Care Med. 10:229 (Abstr.).
• Bell, R.C., and Andrews, C.P.: Pleural Effusions. Respiratory Diseases Digest, 12, 1985.
• Weiner MH, Talbot GH, Gerson SL, Fetchick R, Andrews C, Peacock J] Filice G, Cohen M, Provencher M, Cassileth P. Detection of fungal antigen in body fluids for diagnosis of invasive aspergillosis. Zentralbl Bakteriol Mikrobiol Hyg [A}. 1986 Jul; 261(4):517-22
• Jacobs, R.L., Andrews CP, Jacobs F.O. Hypersensitivity Pneumonitis Treated with an Electrostatic Dust Filter. Ann Intern Med 1989; 110; 115–118.
• Kitziger KJ, Sanders WE, Andrews CP. Acute pulmonary edema associated with use of low-molecular weight dextran for prevention of microvascular thrombosis. J Hand Surg [Am]. 1990 Nov;15(6):902-5.
• Jacobs, R.L., Andrews, C.P., Coalson, J.: Organic Antigen-Induced Interstitial Lung Disease / Diagnosis and Management. Ann. Allergy Asthma Immunol. 2002; 88:30-41.
• Martin,B.G., Andrews, C.P., vanBavel, J.H., Hampel, F.C., Philpot, E.E., Baidoo, C.A., and Richard, K.A.: Intranasal fluticasone proprionate provided greater relief compared to oral montelukast for nasal congestion and other daytime and evening nasal symptoms of seasonal allergic rhinitis. J.Allergy Clin.Immunol 2003; III, number 2, S85 (Abstr.)
• Jacobs,R.L. & Andrews, C.P.: Hypersensitivity pneumonia-nonspecific interstitial pneumonia/fibrosis histopathologic presentation: a study in diagnosis and long-term management. Ann.Allergy Asthma Immunol.2003; 90:265-270
• Jacobs, R.L., Andrews, C.P., Coalson, J.: Hypersensitivity pneumonitis: Beyond classic occupational disease-changing concepts of diagnosis and management. Ann Allergy, Asthma Immunol. 2005; 95:115-128
• Zervos, M, Mandell, L.A, Vrooman, P.S., Andrews, C.P., McIvor, A.: Comparative Efficacies and Tolerabilities of Intravenous Azithromycin Plus Ceftriaxone and Intravenous Levofloxacin with Step-Down Oral Therapy for Hospitalized Patients with Moderate to Severe Community-Acquired Pneumonia. Treat. Respir. Med., 2004 3(5):329-336
• Donohue, J.F., Parsey, M., Andrews, C.P. : Levalbuterol in the treatment of Chronic Obstructive Pulmonary disease. Chest 2005; 128: 42065 (Abstr.).
• Weston-Davies, W.H., Ratner P.H., Andrews C.P., Pasesen G.C., Nuttall P.A.: High affinity histamine binding protein attenuates nasal allergen challenge induced allergic rhinitis. J. Allergy Clin. Immunol. 2006; 117, No.2, S321(Abstr.).
• Martin B.G., Andrews C.P., Van Bavel J.H., Hampel F.C., Klein K.C., Prillamaan B.A., Faris M.A., Philpot E.E.: Comparison of Fluticasone propionate aqueous nasal spray and oral Montelukastt for the treatment of seasonal allergic rhinitis symptoms. Ann. Allergy Asthma Immunol. 2006; 96: 851-857.
• Rennard S.I., Fogarty C., Kelsen S., Long W., Ramsdell J., Allison J., Mahler D., Saadeh C., Siler T., Snell P., Korenblat P., Smith W., Kaye M., Mandel M., Andrews C.P., Prabhu R., Donohue J., Watt R., Schlenker-Hercey R., Barnatham E., Murray J.: The Safety and Efficacy of Infliximab in Patients with moderate-to-severe chronic obstructive pulmonary disease. Submitted for publication.
• Ratner P.H., Andrews C.P., Weston-Davies W.H.: High affinity binding protein attenuates seasonal allergic rhinitis induced by nasal allergen challenge. Submitted for publication.
• Martin, Bruce G.; Ratner, Paul H.; Hampel, Frank C.; Andrews, Charles P.; Toler, Tom; Wu, Wei; Faris, Melissa A.; Philpot, Edward E. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents Allergy and Asthma Proceedings. 2007; 28, No.2: 216-225.
• Ratner P, Andrews C, Van Bavel J, Toler T, Ellsworth A, Philpot E. Once-daily Fluticasone Furoate Nasal Spray Effectively Treats Ocular Symptoms of Seasonal Allergic Rhinitis (SAR) caused by Mountain Cedar Pollen. J Allergy Clin. Immunol 2007; 119, number 2, S231 (Abstr).
• Tashkin DP, Luther M; Andrews CP, Toulinson L, Rinehart M, Denis-Mizek. K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir. Meds. 2008; 102 (4): 479- 87
• Andrews C, Martin R, Jacobs R, Toler T, Prillaman B, Philpot E. Efficacy of fluticosone furoate nasal spray versus oral fexofenadine or nighttime sleep disturbance caused by seasonal allergic rhinitis (SAR) symptoms. (Abstr) Presented at the American College of Allergy and Immunology, November 12, 2007.
• Donohue J, Pursey M, Andrews C, D’Urzo T, Sharma S, Schafer K, Claus R, Baumgartner KA. Evaluation of the efficacy and safety of levalbuteral in subjects with COPD. COPD, 2006; 3 (3): 125-32.
• Martin B, Andrews C, Moher D, Jacobs R, Toler W, Prillamon B, Philpot E. Once-daily fluticasone furoate nasal spray showed greater improvements in relieving nighttime nasal symptoms and increasing peak nasal inspiratory flow vs. oral fexofenadine in subjects with seasonal Allergic Rhinitis. Presented at the American Academy of Allergy Asthma and Immunology, March 15, 2008.
• Andrews C, Martin B, Jacobs R, Diaz J, Prillamon B, Dalal A, Philpot E. Once-daily fluticasone furoate nasal spray showed greater improvement in nocturnal quality of life in subjects with seasonal allergic rhinitis compared with oral fexofenadine. Presented at the American Academy of Allergy Asthma and Immunology, March 15, 2008.
• Andrews C, Martin B, Jacobs R, Mohar D, Diaz J, Amar N, Kaiser H, Vandewalker M, Bernstein J, Toler W, Prillaman B, Dalal A, Lee L, Philpot E. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy and Asthma Proceedings, 2009; 30 (2): 128-138.
Sub Menu
|
San Antonio,
Texas
Charles Andrews,
MD, CPI,
Certified Principal
Investigator